⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 17, 2024Journal of the Peripheral Nervous System

Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy

Yongsheng Zheng Chong Sun Yanyin Zhao Quanhua Meng Jianian Hu Kai Qiao Jian Sun Jianying Xi Sushan Luo Jiahong Lu Chongbo Zhao Jie Lin

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the efficacy and safety of a low-dose, long-term rituximab regimen in the treatment of idiopathic CIDP.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zheng et al. (2024) studied this question.

synapsesocial.com/papers/68e5be6db6db643587555bce https://doi.org/10.1111/jns.12653

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies2024 · 17 citations
2Sustained Remission After Treatment with Rituximab in CIDP Without Nodal/Paranodal AntibodiesOriginal Research · 2026 · 1 citations
3Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy2025
4Long-term follow-up of relapse and remission of CIDP in a Chinese cohort2024 · 5 citations
5P.063 Refractory pediatric CIDP converting to full recovery with rituximab2024 · 1 citations